NovaBay Pharmaceuticals (NBY) Debt to Equity (2016 - 2025)
Historic Debt to Equity for NovaBay Pharmaceuticals (NBY) over the last 10 years, with Q3 2025 value amounting to $0.13.
- NovaBay Pharmaceuticals' Debt to Equity rose 18240.95% to $0.13 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.13, marking a year-over-year increase of 18240.95%. This contributed to the annual value of -$0.5 for FY2024, which is 24686.41% down from last year.
- Latest data reveals that NovaBay Pharmaceuticals reported Debt to Equity of $0.13 as of Q3 2025, which was up 18240.95% from $0.03 recorded in Q2 2025.
- NovaBay Pharmaceuticals' 5-year Debt to Equity high stood at $6.08 for Q1 2024, and its period low was -$1.06 during Q2 2024.
- In the last 4 years, NovaBay Pharmaceuticals' Debt to Equity had a median value of $0.05 in 2024 and averaged $0.49.
- In the last 5 years, NovaBay Pharmaceuticals' Debt to Equity tumbled by 86712.07% in 2024 and then surged by 18240.95% in 2025.
- Over the past 4 years, NovaBay Pharmaceuticals' Debt to Equity (Quarter) stood at $0.01 in 2021, then skyrocketed by 3223.4% to $0.34 in 2023, then plummeted by 246.86% to -$0.5 in 2024, then soared by 126.66% to $0.13 in 2025.
- Its last three reported values are $0.13 in Q3 2025, $0.03 for Q2 2025, and $0.01 during Q1 2025.